HC Wainwright restated their buy rating on shares of Delcath Systems (NASDAQ:DCTH – Free Report) in a research report sent to investors on Friday, Marketbeat.com reports. They currently have a $22.00 price target on the stock.
A number of other equities research analysts also recently commented on the company. Stephens reiterated an “overweight” rating and issued a $25.00 price objective on shares of Delcath Systems in a report on Tuesday, August 6th. Craig Hallum assumed coverage on Delcath Systems in a report on Friday, June 28th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, StockNews.com downgraded Delcath Systems from a “hold” rating to a “sell” rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.50.
Get Our Latest Report on Delcath Systems
Delcath Systems Stock Down 2.0 %
Delcath Systems (NASDAQ:DCTH – Get Free Report) last released its earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). The firm had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. During the same quarter in the previous year, the firm earned ($0.58) EPS. As a group, equities research analysts anticipate that Delcath Systems will post -1.67 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in DCTH. Levin Capital Strategies L.P. grew its stake in Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after acquiring an additional 5,969 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Delcath Systems in the second quarter valued at about $370,000. Renaissance Technologies LLC acquired a new position in Delcath Systems in the second quarter valued at about $694,000. Marshall Wace LLP grew its stake in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after acquiring an additional 6,066 shares during the period. Finally, Legato Capital Management LLC acquired a new position in Delcath Systems in the second quarter valued at about $966,000. 61.12% of the stock is owned by institutional investors and hedge funds.
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Read More
- Five stocks we like better than Delcath Systems
- How to Calculate Stock Profit
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Fintech Stocks With Good 2021 Prospects
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How to Calculate Options Profits
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.